Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test
Shots:
- Chembio to receive funding if reaches certain milestones- to develop POC test utilizing Chembio’s DPP platform and hand-held optical analyzer. The POC test will be built upon Takeda’s biomarker and is expected to provide results in ~15 mins. from a 10µL drop of fingerstick blood
- The collaboration is to combine Chembio's DPP platform and Takeda’s expertise to develop and commercialize a novel POC diagnostic test to improve patient’s health
- Chembio’s DPP technology utilizes a small drop of blood from the fingertip to detect diseases and is also used for DPP HIV 1/2 Assay which has received the US FDA and ANVISA’s approval- CLIA-waiver- WHO prequalification and CE mark
Click here to read full press release/ article
Ref: Globe NewsWire | Image: Takeda
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com